Translate:
EN
Translate:
EN
Signed in as:
filler@godaddy.com
ENTOD Pharmaceutical is the pharmaceutical venture of the Masurkar family, which is a proud pharmaceutical business family that inherits an inspiring legacy that goes back over a 100 years. The company's first manufacturing plant specialised in sterile & injectable products and a dedicated formulation R&D centre was set up on the outskirts of Mumbai in 1977 when it started speciality contract manufacturing services to begin early operations. This was followed by a second manufacturing plant in 1980 to step up capacity and diversify the product range.
In the 80s and 90s the company invested heavily on upgrading their manufacturing infrastructure, upscaling their R&D efforts and growing their client base. During these two decades ENTOD was a trusted speciality contract manufacturer for several Indian multi-national pharma companies who had ventured into the ophthalmic & ENT segments. The company continued contract manufacturing services till the late 1990s after which it made significant changes in business strategy and started its own marketing & sales activities with focus on developing and selling its own branded medicines. At this stage it started recruiting a sales field force and launched its operations in selected states of India.
In the 2000s the company massively upgraded its research infrastructure, quality systems & company protocols. It significantly increased its product range, marketing & sales activities, and improved its sales field coverage to many more states in India. This allowed it to rapidly increase its turnover and gain market share in the ophthalmic, ENT & dermatology pharma segments in India.
In 2010 the company kickstarted its international business operations under ENTOD International, that allowed it to gain access into regulated markets, and boost its exports. It further diversified its product portfolio, actively collaborated with research institutes across India to drive innovation and provided medical academic support to doctors through its smart medical academic outreach programme called ENTOMEET.
In the late 2010s the company increased its sales field strength number to cover every state in India and launched multiple divisions to further penetrate the market and do justice to its large product range.
During the pandemic years, ENTOD made a name for itself internationally when it became the first Indian speciality pharma company to host online academic events for international medical associations, and helped make India into a global hub for medical academics in the ophthalmology and ENT medical fields.
The late Mrs Rukhma Vitthal Masurkar was a single mother and woman pharmaceutical entrepreneur in 1930s rural Karnataka popular for her home-made skin remedies. Having lost her husband at a very young age she moved to Karwar (Karnataka) with her children and supported her family by formulating her own creams and ointments intended for a range of skin conditions. She used to head out to the forest regularly to procure specific plants and herbs of medical value, and return home to grind them down. Then with the knowledge that was passed to her through the generations, she used to formulate them into creams and ointments. Her home-made skin remedies became very popular in Karwar and surrounding villages, and many friends & relatives made her a local household name.
ENTOD Pharmaceuticals was started in 1977 by her son, the late Mr G V Masurkar who was a visionary & pioneer in the Indian pharmaceutical industry in the 1960s and widely regarded as the “Father of Indian Pharma Entrepreneurship”. He was one of the first registered pharmacists in India and was specifically known for introducing the popular painkiller paracetamol in India for the first time during his stint as marketing manager at Duphar Interfran Limited (formerly known as Crookes Interfran Ltd). He was also instrumental in bringing newer innovative medicines of that time into INDIA from the UK & Europe including lacto-calamine lotion, vitamin D etc. into INDIA and making them market successes. Mr G V Masurkar’s entrepreneurial spirit & strong interest in the areas of ophthalmic, ENT & Dermatology medicines encouraged him take an early retirement in the late 1970s from Duphar Interfran Limited and set up his own speciality pharmaceutical venture – ENTOD Pharmaceuticals. The company was started with negligible capital but with a great passion to innovate in the speciality pharmaceutical sector. ENTOD was set up to specialise in the niche field of ophthalmic, ENT & dermatology medicine.His continued passion for quality, research and innovation made ENTOD into a global brand with specialized expertise in the Ophthalmic, ENT and Dermatology medicine fields.
His son Mr Kishore Masurkar is the chairman of ENTOD Pharmaceuticals, a renowned biochemist with impeccable business & entrepreneurial skills and a remarkable vision for global success. He massively upgraded the company's R&D facilities, quality systems and company protocols and increased the product range, marketing & sales activities and number of field based representatives. It is him who has carried forward this great family legacy and been instrumental in the exponential rise of ENTOD Pharmaceuticals in INDIA and abroad. It is due to his vast technical experience, dynamic leadership qualities and strong standing in the industry over the years that has allowed the family business to grow from strength to strength.
Nikkhil K Masurkar belongs to the youngest generation of the Masurkar family and is the CEO of ENTOD Pharmaceuticals. His strong leadership qualities, dynamic entrepreneurial spirit and sharp business acumen together with impressive pharmaceutical & research skills have made ENTOD pharmaceuticals into one of the fastest growing speciality pharmaceutical & healthcare companies in India and abroad. He is a highly qualified research pharmacist from Kings College London (UK) with various clinical pharmacy and formulation research accreditations to his name. He is also a member of the prestigious Royal Pharmaceutical Society in the UK. Nikkhil belongs to a new generation of Indian pharma innovators who are bold enough to push the boundaries when it comes to indigenous pharmaceutical research. Being a maverick in his field and often called as the “Elon Musk of the Indian Pharma Industry” for his groundbreaking innovations in the eye care and skincare segment,
ENTOD Pharmaceuticals today has grown into a full-fledged international research-based pharmaceutical organisation with over 4 decades of expertise in Ophthalmology, ENT and Dermatology medicine. It has a global reach spanning 67 countries worldwide including the UK, Europe and various regulated as well as emerging markets. Globally the company has over 300 medicinal products in its diverse portfolio, a global sales field force of over 1500 and highly experienced Quality Assurance, Production and R&D teams. Its quality systems are certified in Europe and its manufacturing quality standards adheres to international GMP norms.
Domestically, ENTOD is one of the fastest growing top 100 pharma company in India, 3rd largest in the ENT segment and 5th largest in the Ophthalmic segment with a growth rate almost twice as fast as the market. Internationally, ENTOD has already made impressive progress in various emerging and regulated markets and has been rapidly gaining vital market share in these countries due to its strong international brand image and smart marketing strategies.
ENTOD also owns a stake and provides technical assistance to one of India's leading D2C healthcare brand Eyecirque Eye, Skin & Mind Wellness in addition to its pharmaceutical portfolio.
ENTOD's brand new state-of-the-art Department of Scientific and Industrial Research (DSIR) approved ophthalmic, ENT & skincare R&D centre will engage in new molecular discovery, formulation development, personalised ophthalmic medicine and focus on areas such as biologicals, stem cell based therapies and gene therapies. We intend to launch several new speciality medicines in the ophthalmic, ENT and dermatological segments stemming from its completed R&D projects.
ENTOD is also actively investing in generative AI-led drug discovery, quality analysis and a clinical trial programme, and intends to be a pioneer in robotic process automation in sterile manufacturing.
ENTOD’s clinical trial programme includes plans for various phase 2, phase 3 and phase 4 trials over the coming years. It just recently completed two phase 3 clinical trials with first-in-India and first-in-the-world DCGI approvals for treatments intended for myopia and presbyopia, and further clinical trials for new indigenous medicines are currently undergoing. The investments already made and planned for new drug development and clinical trials should allow the company to rapidly commercialise new and innovative therapeutic molecules in India that are the need of the hour.
The company aims to maintain its fast growth by further rapid expansion of its sales field force in both the domestic and international markets supported by the launch of new products and a strong marketing & sales strategy. ENTOD is also in the process of launching a new ophthalmic veterinary division focusing on quality eye care for pets.
To provide a high quality cost-effective solution to the healthcare needs of the global population, and to significantly contribute to the eradication of preventable blindness in the world.
To be continuously & passionately dedicated to the design, development & production of the highest quality pharmaceutical and nutraceutical products through efficiency, innovative thinking & research.
A dharmic MNC that follows a strict ethical business model based on integrity, trust, honesty and family values, and to always ensure that patients' & end-users' interests are given the utmost priority.
Our Products are manufactured at state-of-the art US FDA, MHRA and WHO GMP certified manufacturing units all around the world using the latest manufacturing technologies & machinery. Our factory network has the capacity to manufacture several dosage forms including eye drops, eye gels, eye ointments, ear drops, mouth sprays, tablets,The quality standards incorporated in our production processes conform only to the highest internationally accepted standards. All our units are regularly audit by some of the most stringent drug regulatory authorities.
Our FDA approved international formulation R&D facilities provide us with the technologies to develop and design the highest quality formulations and continuously innovate in various areas of pharmaceuticals. Our research teams consist of some of the most experienced pharmaceutical scientists & chemists engaging in new product development, formulation optimization and clinical trials. Our formulations therefore have the technological edge compared to the more traditional therapies available.
We are certified as a manufacturer and supplier of sterile ophthalmic products under the most stringent of European and Swiss standards. We are ISO 9001:2015 & ISO 13485:2016 certified. Our quality systems are continuously audited internally and externally to ensure that the highest international standards are followed at all times. Our GLP certified laboratories are equipped with the latest analytical & microbiological facilities that allows the most stringent in-house Quality Assurance system checks to be performed on all our products.
We have a committed team of over 1500 field-based sales staff working all over the world to promote our high quality products.
We have a large global distribution network spanning over 67 countries
Disclaimer: All products and therapies (both branded or generic) seen on this website can sold ONLY against the prescription of a registered medical practitioner (doctor) and NOT AVAILABLE to the general public for "Over the Counter (OTC)" purchase.
Copyright © 2024 ENTOD Pharmaceuticals - All Rights Reserved.
This website uses cookies. By continuing to use this site, you accept our use of cookies.